Autres langues Synaptogenix, Inc.

Actions

SNPX

US87167T3005

Marché Fermé - Nasdaq Autres places de cotation 22:30:01 02/05/2024			Varia. 5j.	Varia. 1 janv.
4,76 ^USD	-1,45%		+7,86%	-29,97%

09/04	Synaptogenix, Inc. (NasdaqCM:SNPX) a acquis une participation inconnue dans Psyga Bio Ltd auprès de Cannasoul Analytics Ltd. le 9 avril 2024.	CI
03/04	Synaptogenix prévoit un regroupement d'actions à raison de 1 pour 25 ; les actions chutent	MT

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Synaptogenix Regains Compliance with Nasdaq Minimum Bid Price Requirement for Continued Listing	24/04
Synaptogenix Increases Stake in Innovative Psilocybin Drug Discovery Company through its Partnership with Cannasoul Analytics	09/04
Synaptogenix, Inc. acquired Unknown Stake in Psyga Bio Ltd from Cannasoul Analytics Ltd.	09/04
Synaptogenix Plans 1-for-25 Reverse Stock Split; Shares Fall	03/04
Synaptogenix Announces Reverse Stock Split to Maintain Nasdaq Listing	03/04
Synaptogenix, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	01/04
Synaptogenix President Daniel L. Alkon, M.D. Honored for Scientific Presentation at USC-Sponsored Forum on Age-Related Diseases and Neurodegenerative Disorders	19/12
Synaptogenix Joins Leading Neuroscientists and Academics as Speaker at USC-Sponsored Forum on Age-Related Diseases including Alzheimer's	06/12
Synaptogenix, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	14/11
Synaptogenix Acquires Significant Stake in Cannasoul Analtyics Ltd. Co-founded by the Technion, Israel Institute of Technology	03/11
Synaptogenix Acquires Significant Stake in Cannasoul Analtyics Ltd. Co-founded by The Technion - Israel Institute of Technology	02/11
Synaptogenix, Inc. acquired 25% minority stake in Cannasoul Analytics Ltd. for $4 million.	02/11
Niemann-Pick-Disease Pipeline, FDA Approvals, Clinical Trials, and Emerging Drugs 2023 (Updated)	28/09/23
Synaptogenix Announces Peer-Reviewed Publication of NIH-Sponsored Phase 2 Clinical Trial Results Demonstrating Safe, Significant, and Persistent Benefits of Bryostatin-1 in Advanced Alzheimer's Disease	26/09/23
Synaptogenix : Certificate of Incorporation/Bylaws - Form 8-K	22/09/23
Bryostatin-1 from Synaptogenix Shows Statistically Significant Results as an ALS Treatment in Pre-Clinical Independent Study	07/09/23
Synaptogenix, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	14/08/23
Synaptogenix and Cleveland Clinic to Submit Investigational New Drug Application to FDA for Clinical Trial of Bryostatin-1 in Multiple Sclerosis	20/07/23
Synaptogenix and Cleveland Clinic to Submit Investigational New Drug (IND) Application to FDA for Clinical Trial of Bryostatin-1 in Multiple Sclerosis	19/07/23
Synaptogenix, Inc. and Cleveland Clinic to Submit Investigational New Drug Application to FDA for Clinical Trial of Bryostatin-1 in Multiple Sclerosis	19/07/23

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Synaptogenix, Inc.

Actions

SNPX

US87167T3005

Autres langues

Filtres